Published in Hippokratia on April 01, 2012
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet (2002) 44.28
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (2000) 35.06
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (2006) 15.76
Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 10.45
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet (2009) 9.32
The physiology of glucagon-like peptide 1. Physiol Rev (2007) 9.07
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet (2008) 6.91
Diabetic cardiomyopathy revisited. Circulation (2007) 6.76
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care (2004) 6.64
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet (2008) 6.50
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care (2008) 5.94
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care (2005) 5.77
Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes (1999) 5.10
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia (2009) 4.81
Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care (2009) 4.79
Diabetes, hypertension, and cardiovascular disease: an update. Hypertension (2001) 4.62
Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation (2008) 4.22
Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology (2003) 3.93
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin (2008) 3.58
Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation (2004) 3.51
PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. J Clin Endocrinol Metab (1964) 3.29
Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation (2004) 3.28
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest (1998) 3.18
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology (1995) 3.17
Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci U S A (1992) 3.11
Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol (2009) 2.94
Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail (2008) 2.93
Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care (2007) 2.92
The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med (2007) 2.89
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail (2006) 2.69
Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes (2005) 2.64
GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes (2009) 2.58
Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes (1994) 2.57
Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest (2002) 2.54
Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37). Nature (1993) 2.52
Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol (2007) 2.49
The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis (2006) 2.47
Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens (2003) 2.35
International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev (2003) 2.25
Diabetes and endothelial dysfunction: a clinical perspective. Endocr Rev (2001) 2.22
Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care (1992) 2.21
Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes (2004) 2.17
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care (2007) 2.14
Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol (2001) 2.10
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology (1996) 2.06
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion (1995) 2.05
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab (2006) 2.05
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin Invest (1992) 2.00
Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther (2006) 1.98
Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes (1993) 1.95
Diabetes mellitus and hypertension. Hypertension (1992) 1.93
Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab (2007) 1.82
Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med (2009) 1.73
Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept (2007) 1.72
Coronary vasomotor abnormalities in insulin-resistant individuals. Ann Intern Med (2004) 1.65
Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept (2005) 1.56
New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation (2008) 1.52
The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. J Clin Endocrinol Metab (2002) 1.49
Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes (1996) 1.44
Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation (2002) 1.43
Vasorelaxant effect of glucagon-like peptide-(7-36)amide and amylin on the pulmonary circulation of the rat. Regul Pept (2001) 1.42
Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol (1994) 1.39
GLP-1 and related peptides cause concentration-dependent relaxation of rat aorta through a pathway involving KATP and cAMP. Arch Biochem Biophys (2008) 1.38
Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab Vasc Dis Res (2004) 1.37
Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract (2007) 1.35
Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology (2003) 1.28
Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab (2006) 1.27
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther (2004) 1.25
Circulation and degradation of GIP and GLP-1. Horm Metab Res (2005) 1.21
Coronary heart disease in patients with low LDL-cholesterol: benefit of pravastatin in diabetics and enhanced role for HDL-cholesterol and triglycerides as risk factors. Circulation (2002) 1.18
Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. Cardiovasc Diabetol (2010) 1.17
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides (2003) 1.14
Initiation of increased pancreatic islet growth in young normoglycemic mice (Umeå +/?). Endocrinology (1999) 1.11
Mesenteric vasoconstriction and hindquarters vasodilatation accompany the pressor actions of exendin-4 in conscious rats. J Pharmacol Exp Ther (2005) 1.05
The physiological role of GLP-1 in human: incretin, ileal brake or more? Regul Pept (2005) 1.02
Hyperglycaemia and the vessel wall: the pathophysiological aspects on the atherosclerotic burden in patients with diabetes. Eur J Cardiovasc Prev Rehabil (2010) 1.00
Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin Investig Drugs (2009) 0.99
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans. Am J Physiol Endocrinol Metab (2006) 0.96
Effects of centrally or systemically injected glucagon-like peptide-1 (7-36) amide on release of neurohypophysial hormones and blood pressure in the rat. Regul Pept (2000) 0.95
Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs (2007) 0.94
Complications of diabetes. Prevalence, detection, current treatment, and prognosis. Am J Med (1985) 0.93
Nutrient, neural and endocrine control of glucagon-like peptide secretion. Horm Metab Res (2005) 0.93
Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept (2004) 0.92
Distribution of GLP-1 and PACAP receptors in human tissues. Acta Physiol Scand (1996) 0.88
The changing face of macrovascular disease in non-insulin-dependent diabetes mellitus: an epidemic in progress. Lancet (1997) 0.88
Cardiovascular and pancreatic endocrine responses to glucagon-like peptide-1(7-36) amide in the conscious calf. Exp Physiol (1997) 0.88
Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord (2009) 0.87
Effects of glucagon-like peptide-1 and long-acting analogues on cardiovascular and metabolic function. Drugs R D (2007) 0.86
The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism. Curr Diabetes Rev (2008) 0.82
Treatment of patients with diabetes with GLP-1 analogues or DPP-4- inhibitors: a hot topic for cardiologists? Clin Res Cardiol (2008) 0.80
The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes. Diabetologia (2005) 0.79
Development of preimplantation rabbit embryos in vivo and in vitro. Dev Biol (1974) 4.21
Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med (1998) 1.61
Risk factors for ipsilateral reamputation in patients with diabetic foot lesions. Int J Low Extrem Wounds (2009) 1.55
Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy. A clinical study. Diabetes Care (1994) 1.06
Painful neuropathy and foot ulceration in diabetic patients. Diabetes Care (1993) 1.06
Demethylation of CpG sites in DNA of early rabbit trophoblast. Nature (1981) 0.97
A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med (2013) 0.92
Development of preimplantation rabbit embryos in vivo and in vitro. I. An ultrastructural comparison. Dev Biol (1973) 0.89
The participation of the embryonic genome during early cleavage in the rabbit. Dev Biol (1973) 0.88
Quantitative and qualitative aspects of protein synthesis in the preimplantation rabbit embryo. Exp Cell Res (1969) 0.84
Radical resection of pancreatic cancer. Hepatobiliary Pancreat Dis Int (2008) 0.83
Electron microscopic analysis of RNA transcription in preimplantation rabbit embryos. Chromosoma (1980) 0.82
Proceedings: Phasing of gene products during development. Cancer Res (1974) 0.82
Nucleic acid synthesis in preimplantation rabbit embryos. III. A "dark period" immediately following fertilization, and the early predominance low molecular weight RNA synthesis. J Exp Zool (1977) 0.82
Ultrasonographic features and patterns of regression after conservative treatment of retinoblastoma. Ophthalmologica (1998) 0.81
Comparison of risk factors for foot problems in diabetic patients attending teaching hospital outpatient clinics in four different European states. Diabet Med (1994) 0.81
Epidemiology of diabetes mellitus in the elderly in northern Greece: a population study. Diabet Med (1995) 0.79
Nucleic acid synthesis in preimplantation rabbit embryos. I. Quantitative aspects, relationship to early morphogenesis and protein synthesis. J Exp Zool (1969) 0.79
Ribosome production and protein synthesis in the preimplantation rabbit embryo. Differentiation (1974) 0.78
Microbial community analysis of fouled reverse osmosis membranes used in water recycling. Water Res (2013) 0.77
Polarization of blastomeres in the cleaving rabbit embryo. J Exp Zool (1990) 0.75
Murine teratocarcinoma and the developmental approach to neoplasia. Cancer Res (1976) 0.75
Genetic and biochemical activities in preimplantation embryos. Symp Soc Dev Biol (1975) 0.75
Acronyms and abbreviations. Science (1983) 0.75
Summation: model systems for the study of oncodevelopmental gene expression--murine teratocarcinoma. Cancer Res (1976) 0.75
RNA synthesis in the preimplantation rabbit embryo: radioautographic analysis. Dev Biol (1973) 0.75
Nucleic acid synthesis in preimplantation rabbit embryos. II. Delayed synthesis of ribosomal RNA. J Exp Zool (1971) 0.75
Estimation of the diversity of transcription in early rabbit embryos. Biochem Genet (1973) 0.75
Synthesis of RNA containing polyadenylic acid sequences in preimplantation rabbit embryos. Dev Biol (1973) 0.75
Hypermethylated tRNA in cleaving rabbit embryos. Nature (1973) 0.75
Progesterone concentration in rabbit uterine flushings before implantation. J Reprod Fertil (1976) 0.75
Developmental considerations in the attempt to detect mutations in the mammalian genome. Genetics (1979) 0.75
Spontaneous release of nucleosome cores from embryoblast chromatin. Dev Biol (1982) 0.75